Scalper1 News
Specialty drugmaker Horizon Pharma (HZNP) rose as much as 3.75 early Friday after Leerink launched coverage with an outperform rating. Analyst Jason Gerberry wrote that Horizon’s legacy brands — the arthritis medicines Vimovo and Duexis — have proved surprisingly resilient despite being removed from the preferred formularies of Express Scripts (ESRX) and CVS Health (CVS) this year. The cash flow from those brands should help the company build out Scalper1 News
Scalper1 News